Modulators of AMPK activity.The data in Table 1 are compiled from several publications that describe the molecular mechanisms and tissue-specific effects on AMPK activity in detail (Caton et al., 2010; Dzamko & Steinberg, 2009; Hawley et al., 2010; Maeda et al., 2001; Nagata & Hirata, 2010; Steinberg et al., 2009; Viollet et al., 2010). It should be noted that although in most cases a correlation between treatment and changes in AMPK activity has been demonstrated, the molecular mechanisms are not always fully understood. For example, hormone or cytokine-dependent changes in AMP/ATP ratios may be secondary to other signaling events, such as changes in cAMP concentrations. For some of the treatments, it has yet to be established whether AMPK is
1. Introduction
This chapter begins with general information on the role of 5’-AMP activated kinase (AMPK) in human physiology and the molecular mechanisms that control this kinase. We discuss the functions of AMPK in different tissues and their relationship to type 2 diabetes. AMPK substrates in different subcellular organelles and compartments are described, and we speculate how the localized action of AMPK could help to control type 2 diabetes. Our review concludes with future directions that are based on the compartment-specific action of AMPK to develop new therapeutic strategies for patients with type 2 diabetes.
1.1. AMPK activity is critical to cell physiology in different tissues and organs
AMPK functions as a ser/thr kinase which provides an evolutionary conserved cellular energy sensor. This kinase is a focal point for metabolic control in all eukaryotes, where it regulates many aspects of physiology (Hardie, 2008a; Kim et al., 2009a; Li & McCullough, 2010; Lopaschuk, 2008; Ronnett et al., 2009; Steinberg & Kemp, 2009; Zhang, et al., 2009). It is well-established that AMPK and its yeast ortholog Snf1 control a large number of diverse processes; they include the response to nutrient limitation or other environmental changes, transcription, transport across the nuclear envelope, cell growth, cell cycle progression, mitosis, cell polarity, development, auto- and mitophagy (Amato et al., 2011; Bungard et al., 2010; Egan et al., 2010; Lee et al., 2007; Li & McCullough, 2010; Mirouse et al., 2007; Nagata & Hirata, 2009; Narbonne & Roy, 2009; Quan et al., 2007; Steinberg & Kemp, 2009; Viollet et al., 2009a; Wang et al., 2010; Witczak et al., 2008). As a result of these contributions, AMPK is vital to the function of several organs and tissues in metazoans (Fig. 1).
Owing to its pivotal role in the control of glucose homeostasis, carbohydrate, lipid and protein metabolism AMPK is a key player in many human diseases and disorders (Fogarty & Hardie, 2010; Lage et al., 2008; Towler & Hardie, 2007; Viollet et al., 2009b). In particular, the low activation state of AMPK could contribute to the increase in type 2 diabetes and obesity (Hardie et al., 2006). Moreover, as essential regulator of glucose homeostasis and lipid metabolism, AMPK has become an important therapeutic target in type 2 diabetes and obesity. This is exemplified by metformin and thiazolidinedione derivatives (TZDs); these drugs are used for therapeutic intervention in type 2 diabetes and lead to the activation of AMPK.
2. Organization and activation of AMPK
AMPK senses a drop in cellular energy as it is induced by a reduction in glucose availability or other metabolic stresses. The overall consequence of AMPK activation is a change in metabolism; thus, when the AMP/ATP ratio increases AMPK becomes activated in order to rescue the energy balance. As a result of AMPK activation, the cellular metabolism switches from anabolic to catabolic processes. This metabolic shift is accomplished by the AMPK-dependent phosphorylation of multiple targets which are located in different cellular organelles and compartments (see below).
The heterotrimeric enzyme AMPK (Fig. 2; αβγ) contains one catalytic α subunit that is encoded by two genes (α1 and α2). The regulatory β and γ subunits are encoded by two and three genes, respectively (Hardie et al., 2006). The two β subunits (β1, β2) can be myristoylated and phosphorylated, and these modifications may impact the activation and intracellular localization of AMPK (Oakhill et al., 2010; Warden et al., 2001; see below). The γ subunits (γ1, γ2, γ3) bind AMP and ATP in a mutually exclusive fashion, this AMP binding is important to the activation of the enzyme. The subunit composition of AMPK heterotrimers varies in different tissues and can affect the activation of the kinase (Canto & Auwerx, 2010; Cheung et al., 2000; Steinberg & Kemp, 2009; Viollet et al., 2010).
2.1. Control of AMPK activity by phosphorylation and changes in AMPK concentration
The importance of AMPK as a key regulator in cellular metabolism requires a tight control of the enzyme. The rapid regulation of AMPK activity is based on at least three mechanisms that contribute to AMPK activation (Oakhill et al., 2010; Sanders et al., 2007; Shackelford & Shaw, 2009; Steinberg & Kemp, 2009). (a) The most important step for AMPK activation is the phosphorylation of Thr172 of the α subunit which can be modified by the upstream kinases LKB1, CaMKKβ and TAK1 (Fig. 2). Thr172 is phosphorylated when the energy state of the cell is low, i.e. when the AMP/ATP ratio rises. Under these conditions, AMP binding to the regulatory γ subunit promotes the subsequent Thr172 phosphorylation. LKB1 is the major upstream kinase for this event in tissues like skeletal muscle. The effect of AMP binding depends on the type of γ subunit (Cheung et al., 2000). Specifically, AMP-binding to γ2 subunits leads to the largest increase in AMPK activity. By contrast, a relative small change is observed for the γ3 subunit which is mostly synthesized in glycolytic skeletal muscle. Recent data suggest that the β subunits also play a crucial role in AMPK activation. It was proposed that β subunit myristoylation provides a switch that is a prerequisite for Thr172 phosphorylation (Oakhill et al., 2010). (b) Aside from changes in the AMP/ATP ratio, a rise in intracellular Ca2+ concentrations triggers Thr172 phosphorylation. This modification is mediated by CaMKKβ and particularly important in tissues where LKB1 is not the predominant kinase for Thr172. At present, the role of TAK1 in AMPK activation is not fully understood. (c) AMPK activation can be prolonged by preventing the dephosphorylation of Thr172, a process catalyzed by phosphatases PP2A and PP2C (Kim et al., 2009a; Nagata & Hirata, 2010).
Aside from the dephosphorylation of phospho-Thr172, a negative regulation of AMPK involves the phosphorylation of Ser485/491 by PKC and possibly Akt, whereas the decline in activity by Ser173 phosphorylation was ascribed to PKA (Djouder et al., 2010). Such modification on Ser173 may help to fine tune lipid metabolism in adipose tissue.
The tissue-specific regulation of AMPK activity is likely achieved by the combined effects of upstream activating kinases, inactivating phosphatases as well as the synthesis and degradation of AMPK subunits. For example, LKB1 is particularly important to activate AMPK in skeletal muscle, whereas CaMKKβ is crucial in the brain (Ronnett et al., 2009). On the other hand, TNFα alters AMPK activation by modulating the synthesis of PP2C (Lu et al., 2010; Steinberg et al., 2006). Aside from the rapid control of AMPK activation by phosphorylation, changes in the expression of subunit genes or the turnover of AMPK subunits can help to fine tune AMPK activity in some tissues (Barry et al., 2010; Fukuyama et al., 2007; Hallows et al., 2006; Qi et al., 2008; Niesler et al., 2007; Steinberg et al., 2003).
2.2. Pharmacological compounds and other factors that alter AMPK activity
Previous work established the essential role of AMPK in the regulation of carbohydrate, protein and lipid metabolism; this made AMPK a key target for the treatment of type 2 diabetes, obesity and metabolic syndrome (Gruzman, Babai & Sasson, 2009; Hardie, 2008b; Steinberg & Kemp, 2009; Viollet et al., 2010; Viollet et al., 2009b). Indeed, in a clinical setting AMPK activity is altered with the anti-diabetic drug metformin and other biguanides. The drug-induced activation of AMPK has important consequences for the patient; among these is the improvement of insulin resistance.
Pharmacological drugs have also been critical to define how AMPK mediates metabolic control (see Table 1). These compounds employ a variety of molecular mechanisms that culminate in AMPK activation (Gruzman et al., 2009; Hawley et al., 2010; Mantovani & Roy, 2011). For example, the kinase can be activated by a rise in the AMP/ATP ratio, generation of an AMP mimetic or increase in intracellular Ca2+ concentrations (Hawley et al., 2010). Metformin impacts several biological processes that ultimately activate AMPK. These include changes in the respiratory chain, increased synthesis of the protein deacetylase SIRT1 (which activates LKB1) and activation of TAK1 (Caton et al., 2010; Hawley et al., 2002; Hawley et al., 2010; Xie et al., 2006). Phenphormin promotes the LKB1-dependent activation of AMPK by inhibiting mitochondrial complex I (Hawley et al., 2010). Resveratrol prevents the acetylation and concomitant inactivation of the upstream kinase LKB1, this compound also inhibits mitochondrial ATP synthase and may increase the concentration of adiponectin (Hawley et al., 2010; Wang et al., 2011). AICAR generates the AMP mimetic 5-amino-4-imidazolecarboxamide ribotide (ZMP) and causes a drop in cellular ATP and ADP, which leads to AMPK activation (Hawley et al., 2010). Aside from drugs that activate AMPK, compound C serves as an ATP-competitive inhibitor of AMPK that has been used widely. All of the compounds discussed here are established pharmacological tools that alter AMPK activation or enzymatic activity; they have been useful for the analysis of AMPK
AICAR (5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside) | Generation of ZMP, which functions as an analog of AMP; activation |
Metformin (Biguanide) | Reduces mitochondrial ATP production; activation |
Phenformin | Inhibition of respiratory chain, activation |
Resveratrol | Change in ATP synthase activity; prevents acetylation of LKB1 via modulation of SIRT1; upregulation of adiponectin synthesis and multimerization; activation |
Thiazolidinedione derivatives (TZDs, troglitazone; rosiglitazone, pioglitazone) | Stimulate the expression and secretion of adiponectin; increase in AMP concentration; activation of PPARγ; AMPK activation |
Antimycin A | Inhibition of respiratory chain; activation |
Sodium azide | Inhibition of respiratory chain; activation |
NO | Inhibition of respiratory chain; activation |
Oligomycin | Inhibition of ATP synthase; activation |
Dinitrophenol | Uncoupler of electron transfer/ATP synthesis; activation |
2-Deoxyglucose | Inhibition of glycolysis; activation |
Arsenite | Inhibition of TCA cycle; activation |
β-guanadinopropionic acid | Creatine analog; increases AMP/ATP ratio; activation |
A23187 | Activation by increase in cytosolic calcium ions |
A769662 | Direct AMPK activator |
Compound C (dorsomorphin) | Reversible, ATP-competitive inhibitor |
Insulin | Inhibition of AMPK activation; mediated by Akt kinase |
Ghrelin | Tissue-specific effects; activation in heart and hypothalamus; reduced activity in liver and adipose tissue |
Adiponectin | Activation by increase in AMP concentration |
Resistin | Tissue-specific effects; reduction of AMPK activity in skeletal muscle |
Leptin | Tissue-specific effects; activates α2 heterotrimers; activation in muscle and fat tissue; reduces activity in hypothalamus |
TNFα | Acute and chronic effects; acute: activation; chronic: reduction in activity; increase in PP2C |
IL-6 | Increase in AMP/ATP ratio; activation (note that IL-6 can have different effects on insulin sensitivity) |
CNTF (Ciliary neurotrophic factor) | Tissue-specific effects; activation in muscle; activity reduced in hypothalamus |
UCP1, UCP3 | Uncoupling proteins in mitochondria, change in energy status; activation |
Reduction in glucose availability | Change in energy status; activation |
Rise in Ca2+ concentration, osmotic stress | CaMKKβ activation |
Exercise | Skeletal muscle contraction; activation |
Heat shock, oxidative stress | Environmental stressors; transient activation |
Ischemia/hypoxia, reactive oxygen species | Metabolism/oxidative stress; activation |
3. AMPK functions in different tissues and organs
Although AMPK is present in different tissues and organs, the subunit composition varies, and changes in cell physiology can also alter the profile of expressed subunits (Mahlapuu et al., 2004; Pulinilkunnil et al., 2011; Putman et al., 2007; Quentin et al., 2011; Stapleton et al., 1996; Turnley et al., 1999). Of particular importance at the cellular, organ and organismal level is the ability of AMPK to switch from anabolic to catabolic processes when energy supplies are low. AMPK regulates metabolism and other aspects of cell physiology both under normal and disease conditions; studies with different cells or tissues emphasize the significance of AMPK for cellular metabolism and the response to various forms of stress. Thus, AMPK controls several metabolic pathways that are directly relevant to diabetes and other metabolic diseases or syndromes (Steinberg & Kemp, 2009; Viollet et al., 2010; Zhang et al., 2009). However, AMPK not only provides a sensor for nutrient availability, the kinase is also activated by hormonal signals in peripheral tissues and the hypothalamus (Jorda et al., 2010; Ronnett et al., 2009). Notably, this signaling in the central nervous system contributes to the regulation of food uptake. Research with hepatic, skeletal muscle, adipose, pancreatic and kidney cells is particularly important to our understanding of type 2 diabetes as these cell types are crucial to the etiology or pathophysiology of the disease (Fig. 1). In general, the consequences of AMPK activation can be divided into acute and long-term effects (Mantovani & Roy, 2011; Viollet et al., 2010). Whereas the phosphorylation of key enzymes produces a fast downregulation of ATP-consuming metabolic pathways, long-term effects involve changes in the expression of target genes that control metabolism. Since several recently published excellent reviews covered these topics extensively, Table 2 only summarizes the impact of AMPK activation on tissues that are critical to type 2 diabetes.
Liver | activation of fatty acid oxidation, inhibition of lipogenesis | inhibition of acetyl-CoA carboxylase ACC (Acc1, Acc2) |
reduced cholesterol synthesis | HMG-CoA reductase | |
stimulation of fatty acid uptake | CD36 (a fatty acid translocase) moves to the plasma membrane | |
changes in lipogenesis and glycolysis due to reduced concentration of transcriptional regulators SREBP1 (sterol response element binding protein-1) and ChREBP (carbohydrate response-element binding protein) | inhibits ChREBP by phosphorylation, reduces the transcription of genes encoding SREBP1 and ChREBP | |
increase in mitochondrial biogenesis | increased expression of PGC1α and other genes required for mitochondrial biogenesis | |
glycogen synthesis reduced | inhibition of glycogen synthase | |
inhibition of gluconeogenesis and hepatic glucose production | changes in the activity, concentration or localization of key enzymes or transcriptional regulators; (phosphoenol pyruvate carboxy kinase, HNF4; TORC2, p300) | |
Skeletal muscle | stimulation of glucose uptake; fusion of GLUT4 (glucose transporter) containing vesicles with plasma membrane | phosphorylation of AS160 may promote trafficking of vesicles; increased transcription of GLUT4 gene by phosphorylation of HDAC5 |
increase in mitochondrial biogenesis | increased expression of PGC1α and other genes required for mitochondrial biogenesis | |
increased fatty acid uptake and oxidation | inhibition of ACC | |
reduction in protein synthesis | inhibition of mTOR pathway via modification of mTOR, TSC2 and eEF2 kinase | |
control of glycogen metabolism | inactivation of glycogen synthase | |
Adipose tissue | increase in fatty acid oxidation | inactivation of ACC |
inhibition of lipolysis | phosphorylation of HSL, reduced association of HSL with lipid droplets | |
Pancreas | inhibition of glucose-induced insulin secretion in β cells | reduced trafficking of vesicles containing insulin |
inhibition of transcription of the preproinsulin gene in β cells; stimulation of glucagon secretion in α cells | molecular mechanisms not fully understood | |
Heart | stimulation of glucose uptake by translocation of GLUT4 to the plasma membrane | fusion of GLUT4 containing vesicles with the plasma membrane |
stimulation of glycolysis | activation of 6-phosphofructo-2-kinase → enhances production of fructose 2,6-bisphosphate → stimulates 6-phosphofructo-1-kinase | |
increase in fatty acid oxidation | inactivation of ACC | |
control of glycogen metabolism | contributions of AMPK activity not completely understood at the molecular level | |
Kidney | ameliorates changes linked to diabetic nephropathy | inhibition of mTOR, inhibition of CFTR and other ion channels |
Brain | food intake; multiple pathways affected in the hypothalamus; adiponectin, leptin, insulin and ghrelin control AMPK | control of neuropeptide synthesis |
4. AMPK modulates targets in different subcellular organelles and compartments
4.1. Subcellular distribution of AMPK substrates
The combination and integration of different subcellular events regulated by AMPK enables cells, tissues and organs to coordinate different metabolic pathways in order to achieve and maintain the proper energy balance of the whole organism. Fig. 3 depicts established AMPK substrates according to their presence in different subcellular compartments. Table 3 expands this information and specifies how the AMPK-dependent phosphorylation of individual substrates alters their functions.
It is obvious from Fig. 3 that AMPK phosphorylates a large number of proteins that are associated with distinct organelles or subcellular compartments. Cytoplasmic and mitochondrial substrates of the kinase include enzymes that are involved in fat, protein, glucose and glycogen metabolism. Kinase targets in the plasma membrane consist of ion channels, carriers and receptors, whereas other substrates are linked to the function or trafficking of intracellular membranes. This includes the transport of vesicles containing the glucose transporter GLUT4, because GLUT4 translocation to the plasma membrane is a pre-requisite for efficient glucose uptake in skeletal muscle and other tissues. AS160 and TBC1D1 likely play a role in these processes (Table 3). In the nucleus, the AMPK-mediated modification of transcription factors, transcriptional regulators and a subunit of RNA-polymerase I control the expression of genes that are implicated in specific anabolic and catabolic reactions. The phosphorylation of several of these targets is also critical to the biogenesis of mitochondria and the assembly of ribosomes.
Given the diverse types of AMPK substrates and their presence in different cellular locations, it is helpful to recapitulate their functions (Table 3a). This knowledge is a prerequisite to understand how the dynamic association and action of AMPK in different compartments will impact downstream events.
Substrates that have been established for AMPK heterotrimers that contain the α1 or α2 subunit are shown. For different AMPK substrates the function, effect of AMPK-dependent phosphorylation and the major subcellular localization are depicted. For some substrates, there are cell-type specific differences, and the effect of AMPK-dependent phosphorylation may not be fully understood or controversial. The list of AMPK substrates was compiled from PhosphoSitePlus (phosphosite.org).
Acc1; Subunit of acetyl-CoA carboxylase, ACC | Carboxylates acetyl-CoA, thereby generating malonyl-CoA; this step is rate-limiting for FA biosynthesis. | inhibition | cytoplasm | Sun et al., 2006 |
Acc2; Subunit of acetyl-CoA carboxylase, ACC | Carboxylates acetyl-CoA, thereby generating malonyl-CoA; this step is rate-limiting for FA biosynthesis. | inhibition | mitochondria (outer mitochondrial membrane) | Reihill et al., 2007 |
AMPKα1 | Catalytic subunit of AMPK | potential autoregulation | cytoplasm, nucleus | Stein et al., 2000 |
AMPKβ1 | Regulatory subunit of AMPK | enzymatic activity, localization | cytoplasm, nucleus | Warden et al., 2001 |
CFTR | Cystic fibrosis transmembrane conductance regulator, chloride channel | inhibits PKA-dependent stimulation of CFTR | plasma membrane, ER, cytoplasmic vesicle; early endosome | King et al., 2009; Kong-suphol et al., 2009; Takiar et al., 2011 |
ChREBP | Transcription factor; repressor | inactivation of DNA binding | nucleus, cytoplasm | Kawagu-chi et al., 2002 |
CK1-ε (CK1 epsilon) | Ser/thr kinase; member of the casein kinase 1 (CK1) family; phosphorylates mPer2 | increase of CK1-ε activity; control of circadian clock | cytoplasm, nucleus, cell junction, centrosome | Um et al., 2007 |
CRY1 (crypto-chrome) | DNA photolyase, regulates circadian rhythm | phosphorylation leads to destabilization | nucleus, mitochondria, cytoplasm | Lamia et al., 2009 |
CRTC-1 | CREB-regulated transcriptional coactivator | phosphorylation causes cytoplasmic retention | nucleus, cytoplasm | Mair et al., 2011 |
eEF2K (eEF2 kinase) | Protein kinase; eEF2K modifies and thereby inactivates eEF2 | activation of kinase activity | cytoplasm | Brown et al., 2004 |
eNOS | Endothelial nitric oxide synthase (constitutive), EC 1.14.13.39; regulation of cytoskeletal reorganization | activation, promotes deacetylation by SIRT1 | plasma membrane, Golgi | Chen et al., 2010; Sun et al., 2006 |
GABAB-R1 | GABAB receptor subunit; G-protein coupled receptor | increase in receptor function, promotes functional coupling to K+ channels | plasma membrane, ER, dendrite, axon, postsynaptic membrane | Kura-moto et al., 2007 |
GABAB-R2 | GABAB receptor subunit; G-protein coupled receptor | increase in receptor function, promotes functional coupling to K+ channels | plasma membrane, ER, dendrite, axon, postsynaptic membrane | Kura-moto et al., 2007 |
GBF1; Golgi-specific brefeldin A resistance factor | Guanine nucleotide exchanger for ARF5; mediates ARF5 activation; Golgi to ER trafficking | triggers disassembly of Golgi apparatus | Golgi membrane | Miya-moto et al., 2008 |
GFAT | glutamine-fructose-6-phosphate transaminase 1; EC 2.6.1.16; regulates glucoseflux to hexosamine pathway | 1.4 fold increase in enzymatic activity | cytoplasm | Li et al., 2007 |
GYS1 | Glycogen synthase; EC 2.4.1.11 | inhibits enzymatic activity | cytoplasm | Skurat, et al., 2000 |
H2B | Histone H2B | activates stress-induced transcription | nucleus | Bungard et al., 2010 |
HDAC5 | Histone deacetylase 5; EC3.5.1.98; transcriptional regulator, cell cycle progression, development | reduced binding to GLUT4 promoter → enhanced GLUT4 expression | nucleus (cytoplasm) | McGee et al., 2008 |
HNF4 alpha | Hepatocyte nuclear factor 4 alpha; transcription factor, control of gene expression in hepatocytes | reduced DNA-binding | nucleus | Hong et al., 2003 |
HSL | Hormone sensitive lipase; EC 3.1.1.79; involved in triglyceride lipolysis | inhibition; change in the association with lipid droplets | cytoplasm, lipid droplets | Garton et al. 1989; ; Watt et al., 2006 |
IRS1; adaptor protein | Insulin receptor substrate 1, adaptor protein | modulation of PI3 kinase signaling | cytoplasm | Jakobsen et al., 2001; Tzatsos & Tsich-lis, 2007 |
KCNMA1 iso4; α subunit of BKCa channel | Potassium channel, activated in response to membrane depolarization, oxygen sensing in carotid body | inhibition of potassium currents | integral membrane protein, plasma membrane, axon | Ross et al., 2011 |
Kir6.2 (KCNJ11) | Potassium channel, voltage dependent, inward rectifying | might play a role in insulin secretion | plasma membrane | Chang et al., 2009 |
Kxlink | Kinesin 2; kinesin light chain 1, motor protein | biological role of modification not known | cytoplasm, microtubules | McDo-nald et al., 2009, 2010 |
KPNA2, importin-α1 | Adaptor for classical nuclear import | interferes with nuclear import of HuR | cytoplasm, nucleus, nuclear envelope | Wang et al., 2004 |
mTOR | Ser/thr kinase; EC 2.7.11.1; catalytic subunit of mTORC1 and mTORC2 | links nutrient supply to translation | cytoplasm | Cheng et al., 2004 |
NKCC2 (SLC12A1) | Electroneutral transporter; reabsorption of Na+ and Cl¯; controls cell volume | regulation of transporter activity | plasma membrane | Fraser et al., 2007 |
p27Kip1 (CDKN4) | Cyclin-dependent kinase inhibitor 1B, controls cell cycle progression at G1 | stabilization of p27; linked to autophagy | nucleus | Liang et al., 2007 |
p300 | Protein (histone) acetyltransferase; EC2.3.1.48; transcriptional co-activator | inhibits interaction with nuclear receptors, such as PPARγ | nucleus | Yang et al., 2001 |
p53 | Tumor suppressor, transcription factor, cell cycle arrest, DNA repair, apoptosis | stabilization of p300-p53 interaction; controls cell cycle progression | nucleus | Dornan & Hupp, 2001 |
PFKFB2 | 6-Phosphofructo-2-kinase/ fructose-2,6-bisphosphatase 2; EC 2.7.1.105 or EC 3.1.3.46; glycolysis | activation; stimulation of glycolysis | cytoplasm | Marsin et al., 2000 |
PFKFB3; iPFK2 | similar to PFKFB2; inducible in monocytes | activation | cytoplasm | Marsin et al., 2002 |
PPP1R3C (R5/PTG) | Regulatory subunit of protein phosphatase PP1; controls PP1 activity; targets PP1 to glycogen; stimulation of glycogen synthase | promotes ubiquitination and thereby degradation | glycogen granules | Vernia et al., 2009 |
PPP2R5C (B56 γ) | Regulatory subunit of protein phosphatase PP2A; possible role in the regulation and targeting of PP2A | increases PP2A activity | nucleus, chromosomes | Kim et al., 2009b |
Raf1 | Ser/thr kinase; EC 2.7.11.1; component of Ras→Raf→MEK1/2→ERK1/2 signaling pathway | cytoplasm, plasma membrane | Sprenkle et al., 1997 | |
Raptor | Regulation of mTORC1 (mammalian target of rapamycin complex 1); functions as scaffold | inhibition of mTORC1; cell cycle arrest | cytoplasm | Gwinn et al., 2008 |
Rb | Retinoblastoma protein; regulates cell cycle progression at G1; functions as transcriptional co-regulator; tumor suppressor | control of brain development | nucleus | Dasgupta & Milbrandt, 2009 |
smMLCK | Smooth muscle myosin light chain kinase; ser/thr protein kinase; EC2.7.11.18 | reduces activity of smMLCK | cytoplasm | Horman et al., 2008 |
TBC1D1 | GTPase activating protein Rab family members; regulates glucose transport | induces binding to 14-3-3 proteins | ER | Chen et al., 2008 |
TIF-IA | Transcription initiation factor for RNA-pol I | reduced rDNA transcription | nucleolus | Hoppe et al., 2009 |
TORC2 (CRTC2) | Transducer of regulated CREB protein 2; transcriptional regulator | phosphorylation causes cytoplasmic retention | nucleus, cytoplasm | Koo et al., 2005 |
TSC2 (tuberin) | Generates heterodimer with hamartin (TSC1); TSC1/TSC2 functions as GTPase activator of Rheb | enhances TSC2 activity → inhibition of mTOR | cytoplasm | Inoki, et al., 2003 |
ULK1 | Ser/thr kinase; EC 2.7.11.1; binds to mTORC1 via raptor, binding controlled by nutrient supply | control of autophagy | cytoplasm | Egan et al., 2011 |
VASP | Vasodilator-stimulated phosphoprotein; actin regulator | impairs endothelial actin assembly | cytoplasm, cytoskeleton | Blume et al., 2007 |
ZNF692 (AREBP) | Transcriptional regulator, contains zinc finger | reduction in DNA binding | nucleus | Inoue & Yamau-chi, 2006 |
ACC1 | See above description of AMPKα1 targets | cytoplasm | ||
AS160 (TBC1D4; Akt substrate of 160k) | GTPase activating protein for Rab; implicated in GLUT4 exocytosis in skeletal muscle | not fully understood; may regulate glucose uptake | cytoplasm | Eguez et al., 2005; Treebak et al., 2010 |
HAS2 | Hyaluronic acid synthase 2; EC 2.4.1.212; integral membrane protein | inhibition of enzymatic activity | plasma membrane | Vigetti et al., 2011 |
HDAC5 | See above description of AMPKα1 targets | nucleus | ||
p53 | See above description of AMPKα1 targets | nucleus | ||
PGC1α | PPAR γ coactivator-1; transcriptional co-activator; association with PPARγ; binds to CREB and nuclear respiratory factors; controls mitochondrial biogenesis | phosphorylation alters activity as transcriptional regulator | nucleus | Jager et al., 2007 |
PLD1 | Phospholipase D1 phophatidylcholine specific; EC 3.1.4.4; linked to Ras signaling; involved in membrane trafficking | activation of enzymatic activity | Golgi, ER | Kim et al., 2010 |
4.2. Subcellular distribution and trafficking of AMPK
AMPK is associated with different organelles and subcellular compartments; however, little is known about the dynamic nature of this distribution. Analyses of other signaling pathways have demonstrated that the subcellular localization of kinases is critical for the proper response to extra- and intracellular stimuli, and it is likely that the same scenario applies to AMPK. We will therefore briefly review what is currently known about the subcellular localization and trafficking of AMPK.
AMPK is found in the nucleus and cytoplasm which reflects functions for the enzyme in both locations (Kodiha et al., 2007; Witczak et al., 2008). Although the kinase is associated with multiple compartments, α1 and α2 subunits differ in their nucleocytoplasmic distribution. Under normal growth conditions, α1 is predominantly in the cytoplasm, whereas α2 locates to both the nucleus and cytoplasm (Salt et al., 1998). It was further shown that the nuclear localization sequence (NLS) present in the α2 subunit is required for AMPK nuclear translocation (Suzuki et al., 2007), suggesting that the catalytic α subunit is essential for the proper intracellular localization of the holoenzyme. Our current model of AMPK trafficking proposes that the kinase shuttles between the nucleus and the cytoplasm. Data from our group and others support this idea, as they demonstrated that the nuclear carrier Crm1 is essential for AMPK export from the nucleus to the cytoplasm (Kazgan et al., 2010; Kodiha et al., 2007).
How the β subunit impacts the proper targeting of the holoenzyme is at present not entirely clear. The β1 subunit can be modified posttranslationally, both by phosphorylation and myristoylation, and these modifications were linked to the subcellular targeting of the β1 subunit (Suzuki et al., 2007; Warden et al., 2001). It was proposed that AMPK concentrates in the cytoplasm when the heterotrimeric enzyme contains the β1 subunit (Suzuki et al., 2007). However, this model is difficult to reconcile with the fact that both β1 and β2 subunits can be detected in the nucleus (Kodiha et al., 2007). Furthermore, recent studies suggest that the myristoylation of β1 and β2 subunit is particularly important for AMPK activation, as AMP-dependent myristoylation provides a switch that triggers Thr172 phosphorylation (Oakhill et al., 2010). Although the contribution of β subunits to nuclear and membrane targeting of the holoenzyme is not completely understood at this point, the importance of the β subunit for glycogen binding is well established (Polekhina et al., 2003).
In contrast to the α and β subunits, little is known about the trafficking of AMPK γ subunits. In
Several studies support the model that the intracellular distribution of AMPK in human and other cells is dynamic. This is particularly important in the context of disease, because the distribution of AMPK can be modulated by physiological and environmental stimuli. For example, the α2 subunit translocates to the cell nucleus upon exercise or environmental stress (Kodiha et al., 2007; McGee et al., 2003), indicating that the adaptation of skeletal muscle during exercise or metabolic stress is at least in part mediated by the subcellular relocation of AMPK. Examples of the relocation of AMPK α subunits in human cells exposed to oxidative stress or depleted for energy are shown in Fig. 4 (Kodiha et al., 2007).
The relocation of AMPK subunits in response to physiological changes is not restricted to the α subunits; our previous experiments demonstrated that AMPK β subunits accumulate in the nucleus as well when cells are exposed to oxidative and other forms of stress (Kodiha et al., 2007). Moreover, AMPK localization could be regulated by the circadian rhythm. Specifically, changes in the expression of AMPK subunits may depend on the circadian rhythm; this change in expression will then alter the intracellular distribution of AMPK (Lamia et al., 2009). Since these studies were carried out with mice, it has yet to be shown whether the same applies to humans.
Studies from several laboratories, including our group, defined the signals and mechanisms that determine the trafficking and intracellular distribution of AMPK. Our work also suggested crosstalk between other signaling cascades and the localized action of AMPK (Kodiha et al., 2007 and unpublished). Ultimately, such crosstalk will add to the complexity of downstream events that are modulated by AMPK. Taken together, previous research suggests that AMPK subunits move between different subcellular locations, and it can be expected that the compartment-specific actions of the kinase are linked to the physiological response of cells and tissues.
4.3. How does the compartment-specific action of AMPK impact cellular functions that are relevant to type 2 diabetes?
Type 2 diabetes is associated with the increased risk of a growing number of diseases and pathologies. This is exemplified by renal nephropathy, myocardial disease, stroke, Alzheimer’s and Parkinson’s disease (Almdal et al., 2004; Biessels et al., 2006; Burdo et al., 2009; Hallows et al., 2010; Hu et al., 2007; Maher & Schubert, 2009; Schernhammer et al., 2011). Several drugs are currently used in the clinical setting to activate AMPK in patients suffering from type 2 diabetes or obesity. However, it should be kept in mind that AMPK activation can be beneficial as well as harmful in the ischemic heart, and AMPK activation may be linked to neurodegeneration (Lopaschuk, 2008; Spasic, Callaerts & Norga, 2009; Thornton et al., 2011; Vingtdeux et al., 2011). Thus, activation of AMPK throughout the whole organism or the entire cell of a particular tissue may not always be advantageous. As an alternative approach, we put forward the concept of a compartment-specific modulation of AMPK action. Since AMPK activation can be damaging in the context of some of the complications associated with type 2 diabetes, our approach applies both to the localized activation as well as inhibition of the kinase. We believe that the confined action of AMPK will provide a better therapeutic approach in the future that could reduce the side-effects of AMPK modulators. The simplified model in Fig. 5 summarizes the possible changes of cellular functions that will be induced by targeting AMPK in different subcellular compartments.
In the past few years, significant progress has been made with the identification of AMPK substrates and their links to human disease. As shown in Fig. 3 and Table 3, AMPK modifies targets in different subcellular compartments or organelles. We propose that the modification of these substrates relies on (a) the amount of active AMPK and (b) the intracellular distribution of AMPK. The combination of AMPK activation and subcellular localization will then determine the level of phosphorylation of its substrates and the subsequent changes in cell physiology. Such changes will affect both the rapid response to specific stimuli as well as the long-term modification of metabolism and other processes. In the following, we focus on some of the processes that are controlled by AMPK and linked to type 2 diabetes or the complications associated with the disease.
4.3.1. AMPK targets the protein synthesis apparatus in the cytoplasm
Several of the cytoplasmic substrates of AMPK are essential to promote a fast cellular response to changes in nutrient supply. For example, AMPK phosphorylates cytoplasmic targets, such as eEF2 kinase and mTOR, which regulate protein translation. AMPK-dependent modification of these substrates results in downregulation of protein synthesis. Under some conditions, it could be desirable to preferentially modulate these processes that are associated with cytoplasmic AMPK targets. A possible example of such a scenario is the diabetic kidney (Cammisotto et al., 2008; Hallows et al., 2010; Lee et al., 2007; McMahon et al., 2009). Diabetes-induced renal hypertrophy correlates with diminished AMPK activity and, at the same time, with increased protein synthesis under high glucose conditions (Hallows et al., 2010). AICAR and metformin reduce protein synthesis triggered by high glucose (Lee et al., 2007), but these compounds also produce effects that are unrelated to AMPK activation (Mantovani & Roy, 2011). Thus, stimulating AMPK in the cytoplasm could provide a more focused approach to reduce damage in the diabetic kidney.
4.3.2. AMPK targets associated with the plasma membrane and vesicular trafficking
Several channels and transporters in the plasma membrane are phosphorylated by AMPK and control the secretion of insulin, hyperpolarization of β-cells under low glucose concentration and the response to hypoxia (Beall et al., 2010; Chang et al., 2009; Düfer et al., 2010; Evans et al., 2009; Hallows, 2005; Zheng et al., 2008). Although details of the molecular mechanisms are not always clear and in part controversial, altering the AMPK activity at the plasma membrane has the potential to modify β-cell function. The same principle could also apply to the heart and kidney, where several integral proteins of the plasma membrane are modified by AMPK.
4.3.3. AMPK substrates in the nucleus
In the nucleus, AMPK directly regulates the transcription of genes that control metabolism as well as the biogenesis of mitochondria and ribosomes. As such, AMPK modifies HNF4α, HDAC5, p300, histone H2B, the tumor suppressor p53, PGC1α, and TIF-1A (see Fig. 3 and Table 3). AMPK-dependent phosphorylation of these targets is critical to alter the transcriptional profile, which in turn is necessary to adjust metabolic activities in skeletal muscle, heart, liver and adipose tissues in response to changes in glucose availability. It is reasonable to assume that the modification of transcription factors and transcriptional regulators will rely to a large extent on AMPK in the nucleus. This model is supported by a recent study that shows AMPK to move along genes together with the transcriptional machinery (Bungard et al., 2010). Activation of AMPK in the nucleus could enhance the effects of AMPK on the transcription of several target genes. One of the possible benefits of the activation of nuclear AMPK will be the increase in mitochondrial biogenesis. In the long-term, this could help to stimulate the oxidation of fatty acids and limit the lipotoxicity that is linked to type 2 diabetes (Schrauwen & Hesselink, 2004).
4.3.4. AMPK targets associated with mitochondria
Acc2 is associated with mitochondria and important for the synthesis of malonyl-CoA, an intermediate of fatty acid biosynthesis. AMPK phosphorylates and thereby inactivates Acc, which leads to a reduction in malonyl-CoA concentration. As a consequence,
5. Development of drugs that alter the compartment-specific activity of AMPK
In order to modulate AMPK activity in a fashion that is more localized as compared to the currently used drugs, a number of questions will have to be addressed. This includes the ability to regulate AMPK (a) in different organs or tissues and (b) in specific subcellular locations. Oral administration of metformin is believed to preferentially alter liver metabolism, whereas TZDs and their derivatives affect adipose tissue, skeletal muscle and probably β-cells (Gruzman et al., 2009). One possibility to enhance the tissue-specific action of AMPK will rely on the development of drugs that
Taking into account differences in AMPK subunits could further be exploited to regulate the kinase in different subcellular locations (see section 4.2). Thus, it is believed that the α2 subunit is more concentrated in the nucleus as compared to the α1 subunit; this difference could help to activate mainly nuclear or cytoplasmic pools of the kinase. This line of reasoning could be expanded to the posttranslational modifications of the β subunit, as phosphorylation and myristoylation of the β subunits are implicated in the subcellular distribution of the kinase.
In addition to taking advantage of the differences in AMPK heterotrimers, developing AMPK modulators that accumulate in distinct subcellular compartments will be useful. This strategy could be based on the generation of combimolecules with multiple properties (Rachid et al., 2007). Combimolecules that combine DNA-binding with AMPK activation could enhance the modification of nuclear substrates and thereby alter the gene expression profile. On the other hand, such combimolecules could exploit the differences in lipid composition of intracellular membranes to control the AMPK-dependent phosphorylation of mitochondrial Acc2 or channels residing in the plasma membrane.
6. Conclusions
AMPK and its substrates are critical to the etiology and pathology of type 2 diabetes and other metabolic diseases. Several of the current therapeutic regimens for type 2 diabetes alter AMPK activity, either by affecting the cellular energy status or the concentration of AMPK modulators. More recent studies led to the identification of compounds that directly bind AMPK and change its enzyme activity. We propose that the future design of drugs that takes into account the dynamic subcellular distribution of the kinase and its substrates will help to regulate AMPK not only in different tissues and organs, but also at the subcellular level. In the long term this approach will help to fine-tune AMPK action and the downstream events that rely on the phosphorylation of its targets.
References
- 1.
Almdal T. Scharling H. Jensen J. S. Vestergaard H. 2004 The Independent Effect of Type 2 Diabetes Mellitus on Ischemic Heart Disease, Stroke, and Death: A Population-Based Study of 13 000 Men and Women With 20 Years of Follow-up. 164 1422 1426 - 2.
Amato S. Liu X. Zheng B. Cantley L. Rakic P. Man H. Y. 2011 AMP-Activated Protein Kinase Regulates Neuronal Polarization by Interfering with PI 3-Kinase Localization 332 247 251 - 3.
Barry S. P. Lawrence K. M. Mc Cormick J. et al. 2010 New targets of urocortin-mediated cardioprotection 45 69 85 - 4.
Beall C. Piipari K. Al-Qassab H. Smith M. A. Parker N. Carling D. Viollet B. Withers D. J. Ashford M. L. J. 2010 Loss of AMP-activated protein kinase alpha2-subunit in mouse beta-cells impairs glucose-stimulated insulin secretion and inhibits their sensitivity to hypoglycaemia. 429 323 333 - 5.
Biessels G. J. Staekenborg S. Brunner E. Brayne C. Scheltens P. 2006 Risk of dementia in diabetes mellitus: a systematic review 5 64 74 - 6.
Blume C. Benz P. M. Walter U. Ha J. Kemp B. E. Renne T. 2007 AMP-activated Protein Kinase Impairs Endothelial Actin Cytoskeleton Assembly by Phosphory-lating Vasodilator-stimulated Phosphoprotein.282 4601 4612 - 7.
Browne G. J. Finn S. G. Proud C. G. 2004 Stimulation of the AMP-activated Protein Kinase Leads to Activation of Eukaryotic Elongation Factor 2 Kinase and to Its Phosphorylation at a Novel Site, Serine 398. 279 12220 12231 - 8.
Bungard D. Fuerth B. J. Zeng P. Y. Faubert B. Maas N. L. Viollet B. Carling D. Thompson C. B. Jones R. G. Berger S. L. 2010 Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation 329 1201 1205 - 9.
Burdo J. R. Chen Q. Calcutt N. A. Schubert D. 2009 The pathological interaction between diabetes and presymptomatic Alzheimer’s disease 30 1910 1917 - 10.
Cammisotto P. G. Bendayan M. Cammisotto P. G. Bendayan M. 2008 Adiponectin stimulates phosphorylation of AMP-activated protein kinase alpha in renal glomeruli. 39 579 584 - 11.
Canto C. Auwerx J. 2010 AMP-activated protein kinase and its downstream transcriptional pathways 67 3407 3423 - 12.
Caton P. W. Nayuni N. K. Kieswich J. Khan N. Q. Yaqoob M. M. Corder R. 2010 Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5 205 97 106 - 13.
Chang T. J. Chen W. P. Yang C. Lu P. H. Liang Y. C. Su M. J. Lee S. C. Chuang L. M. 2009 Serine-385 phosphorylation of inwardly rectifying K+ channel subunit (Kir6.2) by AMP-dependent protein kinase plays a key role in rosiglitazone-induced closure of the K(ATP) channel and insulin secretion in rats.52 1112 1121 - 14.
Chen S. Murphy J. Toth R. Campbell D. G. Morrice N. A. Mackintosh C. 2008 Complementary regulation of TBC1D1 and AS160 by growth factors, insulin and AMPK activators 409 449 459 - 15.
Chen Z. Peng I. C. Cui X. Li Y. S. Chien S. Shyy J. Y. 2010 Shear stress, SIRT1, and vascular homeostasis.107 10268 10273 - 16.
Cheng S. W. Y. Fryer L. G. D. Carling D. Shepherd P. R. 2004 Thr2446 Is a Novel Mammalian Target of Rapamycin (mTOR) Phosphorylation Site Regulated by Nutrient Status. 279 15719 15722 - 17.
Cheung P. C. Salt I. P. Davies S. P. Hardie D. G. Carling D. 2000 Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem J346 659 669 - 18.
Da Silva. Xavier G. Leclerc I. Varadi A. Tsuboi T. Moule S. K. Rutter G. A. 2003 Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. 371 761 774 - 19.
Dasgupta B. Milbrandt J. 2009 AMP-Activated Protein Kinase Phosphorylates Retinoblastoma Protein to Control Mammalian Brain Development 16 256 270 - 20.
Djouder N. Tuerk R. D. Suter M. Salvioni P. Thali R. F. Scholz R. Vaahtomeri K. Auchli Y. Rechsteiner H. Brunisholz R. A. Viollet B. Makela T. P. Wallimann T. Neumann D. Krek W. 2010 PKA phosphorylates and inactivates AMPKα to promote efficient lipolysis.29 469 481 - 21.
Dornan D. Hupp T. R. 2001 Inhibition of , 139-144.53 transcription by BOX-I phospho-peptide mimetics that bind to p300. - 22.
Düfer M. Noack K. Krippeit-Drews P. Drews G. 2010 Activation of the AMP-activated protein kinase enhances glucose-stimulated insulin secretion in mouse beta-cells 2 156 163 - 23.
Dzamko N. L. Steinberg G. R. 2009 AMPK-dependent hormonal regulation of whole-body energy metabolism.196 115 127 - 24.
Egan D. F. Shackelford D. B. Mihaylova M. M. et al. 2011 Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy 331 456 461 - 25.
Eguez L. Lee A. Chavez J. A. Miinea C. P. Kane S. Lienhard G. E. Mc Graw T. E. 2005 Full intracellular retention of GLUT4 requires AS160 Rab GTPase activating protein. 2 263 272 - 26.
Evans A. M. Hardie D. G. Peers C. et al. 2009 Ion Channel Regulation by AMPK.1177 89 100 - 27.
Fogarty S. Hardie D. G. 2010 Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. 1804 581 591 - 28.
Fraser S. A. Gimenez I. Cook N. Jennings I. Katerelos M. Katsis F. Levidiotis V. Kemp B. E. Power D. A. 2007 Regulation of the renal-specific Na+-K+-2Cl- co-transporter NKCC2 by AMP-activated protein kinase (AMPK).405 85 93 - 29.
Fukuyama Y. Ohta K. Okoshi R. Suehara M. Kizaki H. Nakagawa K. 2007 Hypoxia Induces Expression and Activation of AMPK in Rat Dental Pulp Cells. 86 903 907 - 30.
Garton A. J. Campbell D. G. Carling D. Hardie D. G. Colbran R. J. Yeaman S. J. 1989 Phosphorylation of bovine hormone-sensitive lipase by the AMP-activated protein kinase. Eur J Biochem179 249 254 - 31.
Gruzman A. Babai G. Sasson S. 2009 Adenosine Monophosphate-Activated Protein Kinase (AMPK) as a New Target for Antidiabetic Drugs: A Review on Metabolic, Pharmacological and Chemical Considerations 6 13 36 - 32.
Gwinn D. M. Shackelford D. B. Egan D. F. Mihaylova M. M. Mery A. Vasquez D. S. Turk B. E. Shaw R. J. 2008 AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint 30 214 226 - 33.
Hallows K. R. 2005 Emerging role of AMP-activated protein kinase in coupling membrane transport to cellular metabolism. 14 464 471 - 34.
Hallows K. R. Fitch A. C. Richardson C. A. Reynolds P. R. Clancy J. P. Dagher P. C. Witters L. A. Kolls J. K. Pilewski J. M. 2006 Up-regulation of AMP-activated Kinase by Dysfunctional Cystic Fibrosis Transmembrane Conductance Regulator in Cystic Fibrosis Airway Epithelial Cells Mitigates Excessive Inflammation. 281 4231 4241 - 35.
Hallows K. R. Mount P. F. Pastor-Soler N. M. Power D. A. 2010 Role of the energy sensor AMP-activated protein kinase in renal physiology and disease Renal Physiology 298, F1067 F1077. - 36.
Hardie D. G. 2008a AMPK: a key regulator of energy balance in the single cell and the whole organism 32 S4, S7 12 - 37.
Hardie D. G. 2008b Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease 582 81 89 - 38.
Hardie D. G. Hawley S. A. Scott J. W. 2006 AMP-activated protein kinase- development of the energy sensor concept.574 7 15 - 39.
Hawley S. A. Gadalla A. E. Olsen G. S. Hardie D. G. 2002 The Antidiabetic Drug Metformin Activates the AMP-Activated Protein Kinase Cascade via an Adenine Nucleotide-Independent Mechanism. 51 2420 2425 - 40.
Hawley S. A. Ross F. A. Chevtzoff C. et al. 2010 Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. 11 554 565 - 41.
Hong Y. H. Varanasi U. S. Yang W. Leff T. 2003 AMP-activated Protein Kinase Regulates HNF4α Transcriptional Activity by Inhibiting Dimer Formation and Decreasing Protein Stability.278 27495 27501 - 42.
Hoppe S. Bierhoff H. Cado I. Weber A. Tiebe M. Grummt I. Voit R. 2009 AMP-activated protein kinase adapts rRNA synthesis to cellular energy supply Proc Natl Acad Sci USA106 17781 17786 - 43.
Horman S. Morel N. Vertommen D. et al. 2008 AMP-activated Protein Kinase Phosphorylates and Desensitizes Smooth Muscle Myosin Light Chain Kinase 283 18505 18512 - 44.
Hu G. Jousilahti P. Bidel S. Antikainen R. Tuomilehto J. 2007 Type 2 Diabetes and the Risk of Parkinson’s Disease. 30 842 847 - 45.
Inoki K. Zhu T. Guan K. L. 2003 TSC2 Mediates Cellular Energy Response to Control Growth and Survival. 115 577 590 - 46.
Inoue E. Yamauchi J. 2006 AMP-activated protein kinase regulates PEPCK gene expression by direct phosphorylation of a novel zinc finger transcription factor BBRC351 793 799 - 47.
Ix J. H. Sharma K. 2010 Mechanisms Linking Obesity, Chronic Kidney Disease, and Fatty Liver Disease: The Roles of Fetuin-A, Adiponectin, and AMPK 21 406 412 - 48.
Jager S. Handschin C. St Pierre J. Spiegelman B. M. 2007 AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. 104 12017 12022 - 49.
Jakobsen S. N. Hardie D. G. Morrice N. Tornqvist H. E. 2001 AMP-activated Protein Kinase Phosphorylates IRS-1 on Ser-789 in Mouse C2C12 Myotubes in Response to 5-Aminoimidazole-4-carboxamide Riboside.276 46912 46916 - 50.
Jordan S. D. Konner A. C. Bruning J. C. 2010 Sensing the fuels: glucose and lipid signaling in the CNS controlling energy homeostasis CMLS67 3255 3273 - 51.
Kawaguchi T. Osatomi K. Yamashita H. Kabashima T. Uyeda K. 2002 Mechanism for Fatty Acid "Sparing" Effect on Glucose-induced Transcription.277 3829 3835 - 52.
Kazgan N. Williams T. Forsberg L. J. Brenman J. E. 2010 Identification of a Nuclear Export Signal in the Catalytic Subunit of AMP-activated Protein Kinase 21 3433 3442 - 53.
Kim A. S. Miller E. J. Young L. H. 2009a AMP-activated protein kinase: a core signalling pathway in the heart.196 37 53 - 54.
Kim K. Baek A. Hwang J. E. Choi Y. A. Jeong J. Lee M. S. Cho D. H. Lim J. S. Kim K. I. Yang Y. 2009b Adiponectin-Activated AMPK Stimulates Dephos-phorylation of AKT through Protein Phosphatase 2A Activation.69 4018 4026 - 55.
Kim J. H. Park J. M. Yea K. Kim H. W. Suh P. G. Ryu S. H. 2010 Phospholipase D1 Mediates AMP-Activated Protein Kinase Signaling for Glucose Uptake. e9600 EOF - 56.
King J. D. Jr Fitch A. C. Lee J. K. Mc Cane J. E. Mak D. O. Foskett J. K. Hallows K. R. 2009 AMP-activated protein kinase phosphorylation of the R domain inhibits PKA stimulation of CFTR 297, C94 101 - 57.
(Kodiha ,M. ,Rassi ,J. G. ,Brown ,C. M. &Stochaj ,U. 2007 ).Localization of AMP kinase is regulated by stress, cell density, and signaling through the MEK-->ERK1/2 pathway. Am J Physiol-Cell Physiol 293, C1427-1436. - 58.
Kongsuphol P. Cassidy D. Hieke B. Treharne K. J. Schreiber R. Mehta A. Kunzelmann K. 2009 Mechanistic insight into control of CFTR by AMPK.284 5645 5653 - 59.
Koo S. H. Flechner L. Qi L. et al. 2005 The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism.437 1109 1111 - 60.
Kuramoto N. Wilkins M. E. Fairfax B. P. et al. 2007 Phospho-Dependent Functional Modulation of GABA(B) Receptors by the Metabolic Sensor AMP-Dependent Protein Kinase.53 233 247 - 61.
Lage R. Diéguez C. Vidal-Puig A. López M. 2008 AMPK: a metabolic gauge regulating whole-body energy homeostasis.14 539 549 - 62.
Lamia K. A. Sachdeva U. M. Di Tacchio L. et al. 2009 AMPK Regulates the Circadian Clock by Cryptochrome Phosphorylation and Degradation.326 437 440 - 63.
Leclerc I. Sun G. Morris C. Fernandez-Millan E. Nyirenda M. Rutter G. 2011 AMP-activated protein kinase regulates glucagon secretion from mouse pancreatic alpha cells.54 125 134 - 64.
Lee M. J. Feliers D. Mariappan M. M. Sataranatarajan K. et al. 2007 A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. 292, F617 F627. - 65.
Li J. Mc Cullough L. D. 2010 Effects of AMP-activated protein kinase in cerebral ischemia.30 480 492 - 66.
Li Y. Roux C. l. Lazereg S. Le Caer J. P. Lapravote O. Badet B. Badet-Denisot M. A. 2007 Identification of a Novel Serine Phosphorylation Site in Human Glutamine:Fructose-6-phosphate Amidotransferase Isoform 146 13163 13169 - 67.
Liang J. Shao S. H. Xu Z. X. Hennessy B. Ding Z. Larrea M. Kondo S. Dumont D. J. Gutterman J. U. Walker C. L. Slingerland J. M. Mills G. B. 2007 The energy sensing LKB1-AMPK pathway regulates27kip1 phosphorylation mediating the decision to enter autophagy or apoptosis. 9, 218-224. - 68.
Lieberthal W. Levine J. S. 2009 The Role of the Mammalian Target Of Rapamycin (mTOR) in Renal Disease.20 2493 2502 - 69.
Lippai M. Csikos G. Maroy P. Lukacsovich T. Juhasz G. Sass M. 2008 SNF4Agamma, the Drosophila AMPK gamma subunit is required for regulation of developmental and stress-induced autophagy.4 476 486 - 70.
Lopaschuk G. D. 2008 AMP-activated protein kinase control of energy metabolism in the ischemic heart. 32, S29 S35. - 71.
Lu J. Wu D. M. Zheng Y. L. Hu B. Zhang Z. F. Shan Q. Zheng Z. H. Liu C. M. Wang Y. J. 2010 Quercetin activates AMP-activated protein kinase by reducing2C expression protecting old mouse brain against high cholesterol-induced neurotoxicity. 222, 199-212. - 72.
Maeda N. Takahashi M. Funahashi T. et al. 2001 PPAR Ligands Increase Expression and Plasma Concentrations of Adiponectin, an Adipose-Derived Protein.50 2094 2099 - 73.
Maher P. A. Schubert D. R. 2009 Metabolic links between diabetes and Alzheimer’s disease.9 617 630 - 74.
Mahlapuu M. Johansson C. Lindgren K. et al. 2004 Expression profiling of the gamma-subunit isoforms of AMP-activated protein kinase suggests a major role for gamma3 in white skeletal muscle. 286, E194 E200. - 75.
Mair W. Morantte I. Rodrigues A. P. C. Manning G. Montminy M. Shaw R. J. Dillin A. 2011 Lifespan extension induced by AMPK and calcineurin is mediated by CRTC-1 and CREB.470 404 408 - 76.
Mantovani J. Roy R. 2011 Re-evaluating the general(ized) roles of AMPK in cellular metabolism.585 967 972 - 77.
Marsin A. S. Bouzin C. Bertrand L. Hue L. 2002 The Stimulation of Glycolysis by Hypoxia in Activated Monocytes Is Mediated by AMP-activated Protein Kinase and Inducible 6-Phosphofructo-2-kinase.277 30778 30783 - 78.
Marsin A. S. Bertrand L. Rider M. H. et al. 2000 Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol10 1247 1255 - 79.
Mc Donald A. Fogarty S. Leclerc I. Hill E. V. Hardie D. G. Rutter G. A. 2009 Control of insulin granule dynamics by AMPK dependent KLC1 phosphorylation.1 198 209 - 80.
Mc Donald A. Fogarty S. Leclerc I. Hill E. V. Hardie D. G. Rutter G. A. 2010 Cell-wide analysis of secretory granule dynamics in three dimensions in living pancreatic beta-cells: evidence against a role for AMPK-dependent phosphorylation of KLC1 at Ser517/Ser520 in glucose-stimulated insulin granule movement.38 205 208 - 81.
Mc Gee S. L. Howlett K. F. Starkie R. L. Cameron-Smith D. Kemp B. E. Hargreaves M. 2003 Exercise Increases Nuclear AMPK alpha2 in Human Skeletal Muscle.52 926 928 - 82.
Mc Gee S. L. van Denderen B. J. W. Howlett K. F. Mollica J. Schertzer J. D. Kemp B. E. Hargreaves M. 2008 AMP-Activated Protein Kinase Regulates GLUT4 Transcription by Phosphorylating Histone Deacetylase 5.57 860 867 - 83.
Mc Mahon K. W. Zanescu D. I. Sood V. Prabhakar S. S. 2009 The Role of 5’-AMP-Activated Protein Kinase (AMPK) in Diabetic Nephropathy: A New Direction?5 44 50 - 84.
Mirouse V. Swick L. L. Kazgan N. St Johnston. D. Brenman J. E. 2007 LKB1 and AMPK maintain epithelial cell polarity under energetic stress. J Cell Biol177 387 392 - 85.
Miyamoto T. Oshiro N. Yoshino K. Nakashima A. Eguchi S. Takahashi M. Ono Y. Kikkawa U. Yonezawa K. 2008 AMP-activated protein kinase phosphorylates Golgi-specific brefeldin A resistance factor 1 at Thr1337 to induce disassembly of Golgi apparatus.283 4430 4438 - 86.
Nagata D. Hirata Y. 2010 The role of AMP-activated protein kinase in the cardio-vascular system.33 22 28 - 87.
Narbonne P. Roy R. 2009 Caenorhabditis elegans dauers need LKB1/AMPK to ration lipid reserves and ensure long-term survival.457 210 214 - 88.
Niesler C. U. Myburgh K. H. Moore F. 2007 The changing AMPK expression profile in differentiating mouse skeletal muscle myoblast cells helps confer increasing resistance to apoptosis.92 207 217 - 89.
Oakhill J. S. Chen Z. P. Scott J. W. Steel R. Castelli L. A. Ling N. Macaulay S. L. Kemp B. E. 2010 beta-Subunit myristoylation is the gatekeeper for initiating metabolic stress sensing by AMP-activated protein kinase (AMPK). Proc Natl Acad Sci USA107 19237 19241 - 90.
Polekhina G. Gupta A. Michell B. J. et al. 2003 AMPK β Subunit Targets Metabolic Stress Sensing to Glycogen. Curr Biol13 867 871 - 91.
Pulinilkunnil T. He H. Kong D. Asakura K. Peroni O. D. Lee A. Kahn B. B. 2011 Adrenergic Regulation of AMP-activated Protein Kinase in Brown Adipose Tissue in Vivo.286 8798 8809 - 92.
Putman C. T. Martins K. J. B. Gallo M. E. Lopaschuk G. D. Pearcey J. A. Mac Lean. I. M. Saranchuk R. J. Pette D. 2007 alpha-Catalytic subunits of 5’AMP-activated protein kinase display fiber-specific expression and are upregulated by chronic low-frequency stimulation in rat muscle. 293, R1325 R1334. - 93.
Qi J. Gong J. Zhao T. Zhao J. Lam P. Ye J. Li J. Z. Wu J. Zhou H. M. Li P. 2008 Downregulation of AMP-activated protein kinase by Cidea-mediated ubiquitination and degradation in brown adipose tissue.27 1537 1548 - 94.
Quan X. Yu J. Bussey H. Stochaj U. 2007 The localization of nuclear exporters of the importin-beta family is regulated by Snf1 kinase, nutrient supply and stress.1773 1052 1061 - 95.
Quentin T. Kitz J. Steinmetz M. Poppe A. Bär K. Krätzner R. 2011 Different expression of the catalytic alpha subunits of the AMP activated protein kinase- an immunohistochemical study in human tissue.26 589 596 - 96.
Rachid Z. Katsoulas A. Williams C. Larroque A. L. Mc Namee J. Jean-Claude B. J. 2007 Optimization of novel combi-molecules: Identification of balanced and mixed bcr-abl/DNA targeting properties.17 4248 4253 - 97.
Reihill J. A. Ewart M. A. Hardie D. G. Salt I. P. 2007 AMP-activated protein kinase mediates VEGF-stimulated endothelial NO production. BBRC354 1084 1088 - 98.
Ronnett G. V. Ramamurthy S. Kleman A. M. Landree L. E. Aja S. 2009 AMPK in the brain: its roles in energy balance and neuroprotection.109 17 23 - 99.
Ross F. A. Rafferty J. N. Dallas M. L. et al. 2011 Selective Expression in Carotid Body Type I Cells of a Single Splice Variant of the Large Conductance Calcium- and Voltage-activated Potassium Channel Confers Regulation by AMP-activated Protein Kinase.286 11929 11936 - 100.
Salt I. Celler J. W. Hawley S. A. Prescott A. Woods A. Carling D. Hardie D. G. 1998 AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform.334 177 187 - 101.
Sanders M. J. Grondin P. O. Hegarty B. D. Snowden M. A. Carling D. 2007 Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade.403 139 148 - 102.
Schernhammer E. Hansen J. Rugbjerg K. Wermuth L. Ritz B. 2011 Diabetes and the Risk of Developing Parkinson’s Disease in Denmark. , in press. - 103.
Schrauwen P. Hesselink M. K. C. 2004 Oxidative Capacity, Lipotoxicity, and Mitochondrial Damage in Type 2 Diabetes.53 1412 1417 - 104.
Shackelford D. B. Shaw R. J. 2009 The LKB1-AMPK pathway: metabolism and growth control in tumour suppression.9 563 575 - 105.
Skurat A. V. Dietrich A. D. Roach P. J. 2000 Glycogen synthase sensitivity to insulin and glucose-6-phosphate is mediated by both NH2- and COOH-terminal phosphorylation sites.49 1096 1100 - 106.
Spasic M. Callaerts P. Norga K. K. 2009 AMP-Activated Protein Kinase (AMPK) Molecular Crossroad for Metabolic Control and Survival of Neurons. Neuroscientist15 309 316 - 107.
Sprenkle A. B. Davies S. P. Carling D. Hardie D. G. Sturgill T. W. 1997 Identification of Raf-1 Ser621 kinase activity from NIH3T3 cells as AMP-activated protein kinase.403 254 258 - 108.
Stapleton D. Mitchelhill K. I. Gao G. et al. 1996 Mammalian AMP-activated Protein Kinase Subfamily.271 611 614 - 109.
Stein S. C. Woods A. Jones N. A. Davison M. D. Carling D. 2000 The regulation of AMP-activated protein kinase by phosphorylation.345 437 443 - 110.
Steinberg G. R. Kemp B. E. 2009 AMPK in Health and Disease.89 1025 1078 - 111.
Steinberg G. R. Michell B. J. van Denderen B. J. W. et al. 2006 Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling.4 465 474 - 112.
Steinberg G. R. Rush J. W. E. Dyck D. J. 2003 AMPK expression and phosphorylation are increased in rodent muscle after chronic leptin treatment. 284, E648 E654. - 113.
Steinberg G. R. Watt M. J. Febbraio M. A. 2009 Cytokine regulation of AMPK signalling.14 1902 1916 - 114.
Sun W. Lee T. S. Zhu M. Gu C. Wang Y. Zhu Y. Shyy J. Y. J. 2006 Statins Activate AMP-Activated Protein Kinase In Vitro and In Vivo.114 2655 2662 - 115.
Suzuki A. Okamoto S. Lee S. Saito K. Shiuchi T. Minokoshi Y. 2007 Leptin Stimulates Fatty Acid Oxidation and Peroxisome Proliferator-Activated Receptor α Gene Expression in Mouse C2C12 Myoblasts by Changing the Subcellular Localization of the α2 Form of AMP-Activated Protein Kinase.27 4317 4327 - 116.
Takiar V. Nishio S. Seo-Mayer P. King J. D. Li H. Zhang L. Karihaloo A. Hallows K. R. Somlo S. Caplan M. J. 2011 Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. USA108 2462 2467 - 117.
Thornton C. Bright N. J. Sastre M. Muckett P. J. Carling D. 2011 AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid beta-peptide exposure. Biochem J434 503 512 - 118.
Towler M. C. Hardie D. G. 2007 AMP-activated protein kinase in metabolic control and insulin signaling. Circulation Res100 328 41 - 119.
Treebak J. T. Taylor E. B. Witczak C. A. An D. Toyoda T. Koh H. J. Xie J. Feener E. P. Wojtaszewski J. r. F. P. Hirshman M. F. Goodyear L. J. 2010 Identification of a novel phosphorylation site on TBC1D4 regulated by AMP-activated protein kinase in skeletal muscle. 298, C377 385 - 120.
Turnley A. M. Stapleton D. Mann R. J. Witters L. A. Kemp B. E. Bartlett P. F. 1999 Cellular Distribution and Developmental Expression of AMP-Activated Protein Kinase Isoforms in Mouse Central Nervous System.72 1707 1716 - 121.
Tzatsos A. Tsichlis P. N. 2007 Energy Depletion Inhibits Phosphatidylinositol 3-Kinase/Akt Signaling and Induces Apoptosis via AMP-activated Protein Kinase-dependent Phosphorylation of IRS-1 at Ser-794.282 18069 18082 - 122.
Um J. H. Yang S. Yamazaki S. Kang H. Viollet B. Foretz M. Chung J. H. 2007 Activation of 5’-AMP-activated Kinase with Diabetes Drug Metformin Induces Casein Kinase 1ε (CKIε)-dependent Degradation of Clock Protein mPer2.282 20794 20798 - 123.
van Oort M. M. van Doorn J. M. Hasnaoui M. E. Glatz J. F. Bonen A. van der Horst D. J. Rodenburg K. W. J. J. P. L. 2009 Effects of AMPK activators on the sub-cellular distribution of fatty acid transporters CD36 and FABPpm.115 137 146 - 124.
Vernia S. Solaz-Fuster M. C. Gimeno-Alcaniz J. V. et al. 2009 AMP-activated Protein Kinase Phosphorylates R5/PTG, the Glycogen Targeting Subunit of the R5/PTG-Protein Phosphatase 1 Holoenzyme, and Accelerates Its Down-regulation by the Laforin-Malin Complex.284 8247 8255 - 125.
Vigetti D. Clerici M. Deleonibus S. Karousou E. Viola M. Moretto P. Heldin P. Hascall V. C. De Luca G. Passi A. 2011 Hyaluronan Synthesis Is Inhibited by Adenosine Monophosphate-activated Protein Kinase through the Regulation of HAS2 Activity in Human Aortic Smooth Muscle Cells.286 7917 7924 - 126.
Vingtdeux V. Davies P. Dickson D. Marambaud P. 2011 AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer’s disease and other tauopathies.121 337 349 - 127.
Viollet B. Athea Y. Mounier R. Guigas B. Zarrinpashneh E. Horman S. Lantier L. Hebrard S. Devin-Leclerc J. Beauloye C. Foretz M. Andreelli F. Ventura-Clapier R. Bertrand L. 2009a AMPK: Lessons from transgenic and knockout animals.14 19 44 - 128.
Viollet B. Lantier L. Devin-Leclerc J. Hebrard S. Amouyal C. Mounier R. Foretz M. Andreelli F. 2009b Targeting the AMPK pathway for the treatment of Type 2 diabetes.14 3380 3400 - 129.
Viollet B. Horman S. Leclerc J. Lantier L. Foretz M. Billaud M. Giri S. Andreelli F. 2010 AMPK inhibition in health and disease.45 276 295 - 130.
Wang A. Liu M. Liu X. Dong L. Q. Glickman R. D. Slaga T. J. Zhou Z. Liu F. 2011 Up-regulation of adiponectin by resveratrol: The essential roles of the Akt/FOXO1 and AMPK signaling pathways and DsbA-L.286 60 66 - 131.
Wang T. Yu Q. Chen J. Deng B. Qian L. Le Y. 2010 2A Mediated AMPK Inhibition Promotes HSP70 Expression in Heat Shock Response. 5, e13096. - 132.
Wang W. Yang X. Kawai T. de Silanes I. L. p. Mazan-Mamczarz K. Chen P. Chook Y. M. Quensel C. Ãhler K. M. Gorospe M. 2004 AMP-activated Protein Kinase-regulated Phosphorylation and Acetylation of Importin α1.279 48376 48388 - 133.
Warden S. M. Richardson C. O’Donnell J. Stapleton D. Kemp B. E. Witters L. A. 2001 Post-translational modifications of the beta-1 subunit of AMP-activated protein kinase affect enzyme activity and cellular localization.354 275 283 - 134.
Watt M. J. Holmes A. G. Pinnamaneni S. K. Garnham A. P. Steinberg G. R. Kemp B. E. Febbraio M. A. 2006 Regulation of HSL serine phosphorylation in skeletal muscle and adipose tissue. 290, E500 E508. - 135.
Witczak C. Sharoff C. Goodyear L. 2008 AMP-activated protein kinase in skeletal muscle: From structure and localization to its role as a master regulator of cellular metabolism.65 3737 3755 - 136.
Xie M. Zhang D. Dyck J. R. B. et al. 2006 A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. USA103 17378 17383 - 137.
Yang W. Hong Y. H. Shen X. Q. Frankowski C. Camp H. S. Leff T. 2001 Regulation of Transcription by AMP-activated Protein Kinase.276 38341 38344 - 138.
Zhang B. B. Zhou G. Li C. 2009 AMPK: An Emerging Drug Target for Diabetes and the Metabolic Syndrome.9 407 416 - 139.
Zheng D. Perianayagam A. Lee D. H. Brannan M. D. Yang L. E. Tellalian D. Chen P. Lemieux K. Marette A. Youn J. H. Mc Donough A. A. 2008 AMPK activation with AICAR provokes an acute fall in plasma [K+]. 294, C126 C135.